Search PubMed⌕ Search

Biomedical subjects

Y Carcassonne

Publications and source records attributed to Y Carcassonne.

At least 73 records · Page 4Linked to original sources
PubMed1986

[Pleurisy in blood diseases: value of thoracoscopic poudrage].

Twenty-five pleural effusions which occurred in 21 lymphoma patients (mean age: 50.6 +/- 4.6 years) were treated by pleural poudrage during thoracoscopy. The effusion was either serofibrinous (32%) or haemorrhagic (41%) or chylous (27%). The mean amount of fluid removed before poudrage was 5.2 +/- 0.6 litres. Thoracoscopy confirmed direct pleural invasion in 95.5% of the cases. Permanent pleural symphysis was obtained in all but 2 patients: one who required one single puncture withdrawing 400 cc, the other with mesothelioma on cured Hodgkin's disease, which was a failure. The mean duration of drainage was 4.8 +/- 0.2 days. The results obtained were identical with those reported with pleurisy in solid tumours.

Adolescent↗
PubMed1985

Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Ciclosporin A (CsA) plasma concentrations were monitored by radioimmunoassay after administration IV and PO to 15 patients before allogeneic bone marrow transplantation. The clearance (10.4 +/- 5.41 1/h), half-life (26.4 +/- 14.6 h), and bioavailability (16% +/- 10%) calculated directly from experimental data showed wide interindividual variations. The kinetics after IV infusion, monitored over 2-5 days, appeared to be triphasic. A three-compartment open mamillary model was thus used to simulate the distribution and elimination kinetics of CsA. The distributive delay between administration PO and absorption in the plasma was approximated using a series of six additional compartments connected with a single transfer rate constant. Then, for each patient, the experimental data corresponding to both IV and PO administration were fitted using a single set of rate constants. Clearance and bioavailability calculated from model parameters correlated well with direct estimations obtained from the areas under the concentration time curves. Drug monitoring and linear modeling will be used in an attempt to achieve stable predetermined plasma concentrations of CsA in bone marrow transplantation patients receiving the drug either IV or PO.

Administration, Oral↗
PubMed1985

Increased prostaglandin E production in malignant lymphomas.

Prostaglandin E (PGE) production was evaluated in 18 normal subjects and 29 patients with Hodgkin's and non-Hodgkin's lymphomas. Plasma PGE levels of patients were found to be highly increased. Increased PGE synthesis was demonstrated in conditioned media from peripheral blood and bone marrow mononuclear cells, arising from the adherent cell fraction enriched in monocytes. No relationship with clinical or pathological findings was observed.

Adolescent↗
PubMed1985

T-lymphocyte subpopulations identified by monoclonal antibodies after human bone-marrow transplantation.

Peripheral T-lymphocyte reconstitution after bone-marrow transplantation, 12 allogeneic and 13 autologous, was studied by indirect immunofluorescence assay using mouse monoclonal antibodies. Abnormal counts were detected in the two major sub-populations of T-cells i.e. helper and T cytotoxic-suppressor lymphocytes, defined by monoclonal antibodies (alpha Leu 3a and B 9.2), and in DR antigen-positive T-cells. The pattern of T-lymphocytes replenishment was identical for both types of transplant, and was not affected by Graft Versus Host disease (GVHD).

Antibodies, Monoclonal↗
PubMed1985

[Digestive localizations of non Hodgkin's malignant lymphoma. Clinical, therapeutic and prognostic aspects. Apropos of 29 cases].

29 cases of non Hodgkin's lymphoma (L.N.H.) involving the gastrointestinal (G.I.) tract were reviewed. Primary G.I. involvement was found in 15 patients (2 occurred after Hodgkin's disease), secondary G.I. involvement in 14 patients. Clinical, barium x-ray studies and endoscopic data, prognostically features, mode and results of therapy were analysed in the two groups. Patients were staged using modified (stage IIE) Ann Arbor system; tumors were classified by the "working formulation of N.H.L. for clinical use" (1982). Patients with primary G.I. stage I E - II E N.H.L. were treated with surgery and radiotherapy or surgery with systemic multiple drugs therapy for patients at high risk for recurrence. Disseminated disease and secondary G.I. N.H.L. were treated by chemotherapy; palliative surgery, with high mortality rate, and radiotherapy were occasionally indicated. 3 patients died and 3 had recurrences (5/6 within 2 years) in the first group. Only 2 patients achieved complete remission in secondary G.I.N.H.L. (median survival time: 14 months). Coeliotomy is necessary for unproved diagnosis or emergencies. This study would indicate that the role of surgery remains important in primary localized G.I. stage I E - II E N.H.L.: although diagnosis might be clearly established on endoscopic biopsies; despite results of primary chemotherapy or radiotherapy on controlling local tumor as reported by others authors. Surgical exploration was an essential step in establishing the extent of disease to plan therapy. Resection prevented the possible local complication associated with primary radiotherapy or chemotherapy. The relative risk of treatment induced second malignancies must be considered in the design of adjuvant therapy.

Adolescent↗
PubMed1984

[Factor X deficiency and systemic amylosis].

The case of a 52-year-old patient with systemic amylosis diagnosed upon examination of an osteomedullary biopsy specimen is reported. The most prominent clinical manifestation was a major hemorrhagic syndrome which was recognized as being a result of severe factor Stuart deficiency. The new classification of amyloses based on the latest biochemical and immunological findings is recalled. Current physiopathogenic speculations put emphasis on plasmocyte-macrophage cooperation. Lastly, factor Stuart deficiency, which is as classical as it is uncommon, could originate in the particular affinity of amyloid fibers for this factor and in a "mass effect" (quantity of amyloid substance directly exposed to blood flow), explaining why splenectomy is effective in some instances.

Amyloid↗
PubMed1984

[Morphological study of 4 cases of T lymphoma].

Modern physiopathological studies of the lymphoid system have enabled accurate immunological identification of the different B lymphopathies. Concurrently, the categorization of T proliferations is evolving. In addition to the morphologically well known categories of T lymphomas, three different histological entities are at present termed T lymphomas by anglo-saxon authors: lymphoma with pleiomorphic cytology, or large cell lymphoma, whose identification seems to be the most difficult; Pinkus lymphoma, with subcutaneous clinical localizations which differ from the initial sites of lymphomas, composed of lymphoid cells whose morphology is very characteristic; Lennert lymphoma, whose precise nature is still under debate, but that has been immunologically identified as a T neoplasm by some American authors. We report four observations that exemplify the complex identification of these lymphomas. One case is a Lennert lymphoma which developed into T immunoblastic lymphoma rising the problem of the relationships between these two diseases. The link between these diverse histological pictures is the T immunological identification of the proliferation for which the routine use of monoclonal antibodies should prove helpful.

Adult↗
PubMed1984

Primary pedunculated fibrosarcoma of the peritoneum: a case report.

Fibrosarcoma is a primitive, mesenchymal tumor frequently arising from superficially located soft tissues. A case of a primary intraperitoneal, pedunculated fibrosarcoma is reported, initially presenting as an abdominal mass protruding into a large incisional hernia of the anterior abdominal wall. Despite total tumor resection, multiple intraperitoneal tumor nodules of varying sizes were found and resected six months and one year later. The patient died 18 months after the first surgical intervention. This case illustrates the highly malignant behavior and poor prognosis of fibrosarcomas of the peritoneum.

Aged↗
PubMed1984

Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.

Determination of methotrexate (MTX) kinetics after an IV bolus (50 mg/m2) allows prediction of the steady-state plasma level of this drug during a constant infusion. This prediction allows high-dose MTX (HD-MTX) therapy without major toxicity. Patients with head and neck carcinoma received HD-MTX and vindesine (VDS) infusions concomitantly. The therapeutic survey of these patients showed that the predicted plasma level of MTX was not achieved in the presence of VDS. Moreover, the computed dose of MTX had to be increased by a larger amount if the MTX plasma clearance after the identification IV push was low (less than 9 l/h). In the presence of VDS, the creatinine clearance is lower than when MTX is infused alone, and MTX renal elimination is identical (MTX or MTX + VDS infusions). Thus it seems that the decrease of the MTX plasma level during MTX-VDS infusion could be due to an increase of cellular incorporation.

Adult↗
PubMed1984

Assay of methotrexate and 7-hydroxymethotrexate by gradient-elution high-performance liquid chromatography and its application in a high-dose pharmacokinetic study.

A paired-ion high-performance liquid chromatographic method is described for the simultaneous determination of methotrexate (MTX) and its major metabolise, 7-hydroxymethotrexate (7-OH-MTX), in plasma and urine. In addition, this technique permits the separation of other known metabolites of MTX, such as DAMPA and MTX-polyglutamates. After selective extraction on an anion-exchange resin column, both compounds and the internal standard, aminopterin, were separated on a reversed-phase octadecylsilane column with UV-detection at 313 nm. The detection limits for plasma and urine samples were approximately 40 ng/ml (8.8 x 10(-8) M) for MTX and 100 ng/ml (2.1 x 10(-7) M) for 7-OH-MTX. This method was applied in pharmacokinetic studies following 24-h infusion of high-dose MTX in four patients during two successive treatments. After the end of the infusion, the mean apparent half-life for the metabolite was 19.1 h, while that for MTX was 8.8 h. A stepwise increase in the plasma concentrations of both MTX and its metabolite was observed during the second MTX infusion. This increase was reflected in the cumulative urinary excretion of both drug and its metabolite.

Journal Article↗